Patents by Inventor Avi Ashkenazi

Avi Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of inflammatory disorders with STIgMA immunoadhesins
    Patent number: 7192589
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: March 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, Menno Van Lookeren, William I. Wood
  • Compositions and methods for the diagnosis and treatment of tumor
    Publication number: 20070054361
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: July 13, 2006
    Publication date: March 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin Gurney, Paul Polakis, Andrew Polson, William Wood, Thomas Wu, Zemin Zhang
  • Method for treating tumors using anti-osteopontin antibodies
    Publication number: 20070041983
    Abstract: The present invention is directed to compositions of matter useful for the treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 28, 2006
    Publication date: February 22, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Robert Pitti, Thomas Wu, Zemin Zhang
  • Apo-2DcR
    Publication number: 20070041969
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: June 23, 2006
    Publication date: February 22, 2007
    Inventors: Avi Ashkenazi, Kevin Baker, Austin Gurney, William Wood
  • Apo-2 ligand
    Publication number: 20070036782
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: December 19, 2005
    Publication date: February 15, 2007
    Inventor: Avi Ashkenazi
  • Apo-2DcR
    Publication number: 20070037191
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Kevin Baker, Anan Chuntharapai, Austin Gurney, Kyung Kim, William Wood
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20070031901
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 8, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Audrey Goddard, Paul Godowski, Austin Gurney, Paul Polakis, P. Williams, William Wood, Thomas Wu, Zemin Zhang
  • Use of A33 antigens and jam-it
    Publication number: 20070031405
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 8, 2007
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin Gurney, Mary Napier, Daniel Tumas, William Wood
  • APO-2 ligand-anti-her-2 antibody synergism
    Publication number: 20070026001
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Gail Phillips
  • APO-2L receptor agonist and CPT-11 synergism
    Publication number: 20070026000
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Mark Benyunes, Ralph Schwall
  • TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA INHIBITORS
    Publication number: 20070020268
    Abstract: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-? inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
    Type: Application
    Filed: July 27, 2006
    Publication date: January 25, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Rebecca Ward
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Publication number: 20070015247
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Application
    Filed: June 15, 2006
    Publication date: January 18, 2007
    Inventors: Avi Ashkenazi, Anan Chuntharapai, K. Kim
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20060275864
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: October 20, 2004
    Publication date: December 7, 2006
    Applicant: GENENTECH, INC.
    Inventors: Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary Gerritsen, Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, Kenneth Hillan, Ivar Kljavin, Jennie Mather, James Pan, Nicholas Paoni, Margaret Roy, Timothy Stewart, Daniel Tumas, P. Williams, William Wood
  • Apo-2 receptor
    Publication number: 20060251647
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: November 9, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20060246540
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: September 29, 2005
    Publication date: November 2, 2006
    Inventors: Avi Ashkenazi, Kevin Baker, David Botstein, Luc Desnoyers, Dan Eaton, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary Gerritsen, Audrey Goddard, Paul Godowski, Austin Gurney, Ivar Kljavin, Jennie Mather, Mary Napier, James Pan, Nicholas Paoni, Margaret Roy, Timothy Stewart, Daniel Tumas, Colin Watanabe, P. Williams, William Wood, Zemin Zhang
  • Use of A33 antigens and JAM-it
    Publication number: 20060233803
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.
    Type: Application
    Filed: June 19, 2006
    Publication date: October 19, 2006
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin Gurney, Mary Napier, Daniel Tumas, Menno Lookeren, William Wood
  • Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
    Patent number: 7115713
    Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: October 3, 2006
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, William I. Wood
  • DNA 19355 polypeptide, a tumor necrosis factor homolog
    Publication number: 20060216270
    Abstract: A tumor necrosis factor homolog, identified as DNA19355, is provided. DNA19355 polypeptide has apoptotic activity in mammalian cancer cells and may be involved in proinflammatory responses. Nucleic acid molecules encoding DNA19355, chimeric molecules and antibodies to DNA19355 are also provided.
    Type: Application
    Filed: February 14, 2006
    Publication date: September 28, 2006
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Kevin Baker, Paul Godowski, Austin Gurney, Melanie Mark, Scot Marsters, Robert Pitti
  • Apo-2LI and Apo-3 polypeptides
    Publication number: 20060194286
    Abstract: Novel polypeptides, designated Apo-3 and Apo-2LI, involved in apoptosis are provided. Compositions including chimeric molecules, nucleic acids, and antibodies are also provided.
    Type: Application
    Filed: February 21, 2006
    Publication date: August 31, 2006
    Inventor: Avi Ashkenazi
  • Methods of using death receptor agonists and EGFR inhibitors
    Publication number: 20060188498
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
    Type: Application
    Filed: February 18, 2005
    Publication date: August 24, 2006
    Inventor: Avi Ashkenazi